WASHINGTON – US health experts said Tuesday they are halting clinical trials of convalescent blood plasma in patients with mild to moderate Covid symptoms after preliminary results showed no benefit from the treatment.
The trial that began in August involved just over 500 people who went to emergency rooms but did not need to be hospitalized.
The people chosen for the study also had risk factors such as obesity, high blood pressure, diabetes or heart trouble.
Some of them received the treatment — blood plasma from people who had Covid and overcame it — and others got a placebo.
Doctors looked at how many needed additional care or outright hospitalization, or who died, i…
Keep on reading: US halts trials of plasma transfusions for COVID-19 patients